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Introduction: Airway obstruction and possible concomitant pulmonary diseases in COPD 
cannot be identified conventionally with any single diagnostic tool. We aimed to diagnose and 
grade COPD severity and identify pulmonary comorbidities associated with COPD with ventila-
tion/perfusion single-photon emission computed tomography (V/P SPECT) using Technegas 
as the functional ventilation imaging agent.
Methods: 94 COPD patients (aged 43–86 years, Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) stages I–IV) were examined with V/P SPECT and spirometry. Ventilation 
and perfusion defects were analyzed blindly according to the European guidelines. Penetration 
grade of Technegas in V SPECT measured the degree of obstructive small airways disease. 
Total preserved lung function and penetration grade of Technegas in V SPECT were assessed 
by V/P SPECT and compared to GOLD stages and spirometry.
Results: Signs of small airway obstruction in the ventilation SPECT images were found in 
92 patients. Emphysema was identified in 81 patients. Two patients had no signs of COPD, but 
both of them had a pulmonary embolism, and in one of them we also suspected a lung tumor. 
The penetration grade of Technegas in V SPECT and total preserved lung function correlated 
significantly to GOLD stages (r=0.63 and -0.60, respectively, P,0.0001). V/P SPECT identi-
fied pulmonary embolism in 30 patients (32%). A pattern typical for heart failure was present 
in 26 patients (28%). Parenchymal changes typical for pneumonia or lung tumor were present 
in several cases.
Conclusion: V/P SPECT, using Technegas as the functional ventilation imaging agent, is a 
new tool to diagnose COPD and to grade its severity. Additionally, it revealed heterogeneity of 
COPD caused by pulmonary comorbidities. The characteristics of these comorbidities suggest 
their significant impact in clarifying symptoms, and also their influence on the prognosis.
Keywords: V/P SPECT, COPD, imaging interpretation criteria, Technegas, pulmonary 
comorbidities
Introduction
COPD is a major cause of morbidity and mortality. The global number of COPD cases 
was estimated to be 384 million in 2010, with a prevalence of 11.7%.1 In China, COPD 
is the second leading cause of morbidity and mortality. In 2004, the overall prevalence 
of COPD was 8.2% in seven Chinese provinces and cities.2 Both smoking and biomass 
fuel consumption are important etiological factors.3,4 Programs for improved patient 
management in clinical practice have been organized in China.5
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COPD is characterized by airflow limitation and abnormal 
inflammatory response.6,7 The changes include increased 
airway resistance due to airway obstruction, inflammation 
and luminal plugs, and increased compliance caused by 
parenchymal destruction and loss of alveolar attachments. 
There are also vascular changes due to inflammatory 
remodeling, with progressive vascular occlusion and loss 
of vasculature in areas with emphysematous destruction. 
Comorbidities like left heart failure (LHF), lung cancer, pul-
monary embolism (PE), and atherosclerosis are common.8,9 
Hence, COPD is a heterogeneous condition, and the clinical 
presentation, pathophysiology, disease progression, and 
response to therapy vary between patients.10
In general, COPD is diagnosed and graded by spirometer 
indices like FEV
1
 (forced expiratory volume in 1 second), 
FVC (forced vital capacity), and FEV
1
 in relation to FVC, 
or FEV%.7 Lowering of FEV% measures the degree of 
airflow obstruction, predominantly in large and intermedi-
ate airways, but provides no explanation of the underlying 
pathophysiology.11 It is therefore generally accepted that 
FEV
1
 by itself cannot describe the complexity of COPD and 
that FEV
1
 alone cannot be used for optimal assessment and 
management of the disease.7,12 
Individualized treatment of COPD is growing, and there 
is a need for better ways to categorize patients into different 
phenotypes, and in the best case endotypes, to be able to 
optimize therapy, follow and predict disease progression, and 
measure response to therapy.10 Different imaging modalities 
are generating interest within the field of COPD.13
Tomographic lung scintigraphy (ventilation/perfusion 
single-photon emission computed tomography: V/P SPECT) 
is a nuclear medicine investigation technique that gives a 
3-dimensional functional map of the ventilation and perfusion 
of the lungs. Its primary use is in the diagnosis and follow-up 
of PE.14–16 The introduction of ultrafine aerosols like Tech-
negas has expanded the field of application for V/P SPECT, 
and airway obstruction is no longer considered a problem for 
PE diagnosis, which was the case for previous hydrosoluble 
aerosols.17 Moreover, V/P SPECT has been shown to have 
applications in COPD and to be more sensitive than CT and 
FEV
1
 in detecting early airway changes.18–20 V/P SPECT can 
be used to differentiate between healthy controls and COPD 
patients and to grade the degree of small airway obstruction in 
COPD.19,21 Furthermore, it may be used to semi-quantitatively 
assess the degree of lung function reduction in obstructive 
lung disease and PE.19,22
We aimed to evaluate V/P SPECT in the diagnosis of 
COPD, in grading the severity of COPD, and in specifying 
the role of additional pulmonary comorbidities inducing 
heterogeneity.
Patients and methods
Ninety four patients with a clinical diagnosis of COPD, 
based on the 2011 revision of Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria with a post-
bronchodilator ratio of FEV
1
 over FVC ,0.70, were enrolled 
in 3 hospitals in Shanghai and Chongqing in an interna-
tional multicentre trial among patients who had a current 
or former smoking history (.10 pack years) or a verified 
biomass exposure, who were aged 40 years or older, and 
who had stable disease and no exacerbation or respiratory 
infection within 6 weeks prior to study entry. The patients 
had no allergic diathesis or a history of bronchial asthma, 
domiciliary oxygen, and no history of pulmonary resection, 
or concomitant major illness, or difficulties in cooperation. 
Pregnant or breast-feeding women were excluded.
All patients signed an informed consent form for partici-
pation prior to study entry, according to the ICH Harmonized 
Tripartite Guideline for Good Clinical Practice. This pro-
spective study was approved by the Human Research Ethics 
Committee of Changzheng Hospital and Huadong Hospital 
in Shanghai (the Shanghai Changzheng Hospital biomedical 
science research ethics committee) and Xinqiao Hospital in 
Chongqing (No 2 affiliate hospital of the 3rd Military Medical 
University medical ethics committee).
Clinical symptoms, diagnoses, and medications were 
listed in the case record form. The subjects were reevaluated 
at the study visit by post-bronchodilator spirometry, per-
formed according to ATS/ERS standards.23 A MasterScope™ 
spirometer (Jaeger, Würzburg, Germany) was used to measure 
pulmonary function by FEV
1
, FVC, and their ratio (FEV
1
/ 
FVC = FEV%). GOLD criteria were used at the study visit 
to grade the severity of airflow limitation in COPD patients 
to clinical stage I or mild COPD (FEV
1
 .80% predicted), 
stage II or moderate COPD (FEV
1
 50%–80% pre-
dicted), stage III or severe COPD (FEV
1
 30%–50% pre-
dicted), and stage IV or very severe COPD (FEV
1
 ,30% 
predicted).24
V/P sPeCT protocol
V/P SPECT imaging was performed in accordance with the 
recommendations of the European Association of Nuclear 
Medicine.25,26 In short, a large-field-of-view dual-head 
gamma-camera with a low-energy, all-purpose collimator 
was used. Technegas (Cyclomedica Ltd, Kingsgrove, NSW, 
Australia) was inhaled until 30 MBq had reached the lungs, 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
21
4.
59
.1
63
 o
n 
11
-J
ul
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1581
COPD with V/P sPeCT
and ventilation tomography followed. After that, with the 
patient in a carefully maintained supine position, 140 MBq 
99mTc-MAA was slowly injected intravenously. Then, perfu-
sion tomography was performed. Acquisition was performed 
in a 64×64 matrix, zoomed to a pixel size of 6.8 mm with 
128 projections over 360 degrees. For the ventilation study, 
each step was of 10s duration, and for the perfusion study, 
5s duration were used for each step. Reconstruction was 
performed using ordered subsets expectation maximization 
with 8 subsets and 2 iterations.
V/P SPECT was interpreted centrally by experienced 
nuclear medicine physicians, blinded to other information, 
and read according to the guidelines of the EANM.25 The 
degree of obstructive small airways disease was visually 
graded according to a predefined 4-point scale (0–3) based 
on the ventilatory impairment shown by the penetration grade 
of Technegas in V SPECT (Vgrade), as described earlier.27 
V/P SPECT images were reviewed according to a clinical 
routine assessing the presence of PE, LHF, emphysema, 
pneumonia, or suspicion of tumor.15,25,28,29
Ventilation/perfusion defects were quantified by count-
ing segments or subsegments showing complete or reduced 
ventilation and/or perfusion defects and were expressed in 
% of the total lung parenchyma.19,22,30 The degree of obstruc-
tive disease, if present, was described as mild (approximately 
affecting 20% of the lung function), moderate (20%–50%), 
or severe (.50%). The extent of matched, mismatched, and 
reverse mismatched defects was expressed as a percentage 
of the total lung volume. The sum of these was used to 
estimate the extent of the total reduction in lung function. 
To be regarded as an area with fully preserved lung func-
tion, both ventilation and perfusion had to be normal and 
matched. Total preserved lung function was quantified semi-
quantitatively and described in % of the total estimated lung 
volume (TPLF%).
statistics
Prism 6 software (GraphPad Software, Inc. La Jolla, CA, 
USA) was used for statistical analysis. Baseline character-
ization of the patients and the groups of patients formed on 
the basis of classification of their disease were assessed by 
descriptive analyses in terms of age, gender, medical history, 
etc. Correlation analyses were done using Pearson correlation 
coefficients (r). Linear regression analysis was used to evalu-
ate the relationship between the V/P SPECT measures and 
pulmonary function tests. For group comparisons, analysis 
of variance followed by post-tests or Mann–Whitney test 
for comparison of two groups were applied. Results are 
expressed as mean and standard deviation or mean and 95% 
confidence intervals. A value of P-value less than 0.05 was 
considered to be significant.
Results
Patient characteristics are shown in Table 1. Eighty-eight 
percent of the patients were smokers (28% currently smoking), 
and 12% were exposed to biomass smoke only. Eighty nine 
percent of the patients were males. Seventy seven percent of 
the patients were treated with a combination therapy of inhaled 
corticosteroid and long-acting beta-agonist (ICS+LABA), 50% 
were treated with a long-acting muscarinic antagonist (LAMA), 
and 13% used theophylline. LABA was never given as a 
monotherapy. Seventeen percent of the patients used LAMA 
as a monotherapy, 6% used theophylline combined with 
SABA and/or SAMA. Short-acting beta-agonists (SABAs) as 
needed and/or short-acting muscarinic antagonists (SAMAs) as 
needed were used as rescue therapy. With this medication, the 
post-bronchodilatation FEV
1
 and FVC of the patients ranged 
from 21%–108% (mean 50%) and 28%–125% (mean 82%), 
respectively, of the predicted value. FEV% ranged between 
25%–86% (mean 51%). Typical clinical symptoms were cough 
(91%), wheeze (89%), expectoration (77%), chest tightness 
(45%), and breathlessness (31%). Fever (5%), chest pain (1%), 
or hemoptysis (1%) were occasionally present. GOLD grading 
of COPD severity was mild in 6%, moderate in 35%, severe in 
49%, and very severe in 10% of cases. Fifty-seven percent of 
patients had experienced at least one exacerbation of COPD 
during the past year. The number of exacerbations per patient 
within the past 12 months ranged from 0–6 (mean 1).
Abnormal Vgrade as a sign of obstructive small airways 
disease in the ventilation SPECT images was found in 
92 patients (98%, Figure 1). This ventilatory impairment 
Table 1 Characteristics of the patients
94 COPD patients Mean ± SD Range
age (years) 68±9 43–86
height (cm) 164±7 146–178
Weight (kg) 66±11 38–98
BMI (kg/m2) 24±4 16–35
Pack years 33±21 0–104
number of exacerbations within the 
past 12 months
1.1±1.3 0–6
spirometry
– Post-bronchodilatation FeV1 50%±18% pred 21%–108% pred
– Post-bronchodilatation FVC 82%±22% pred 28%–125% pred
– Post-bronchodilatation FeV1/FVC 51%±15% 25%–86%
– acute bronchodilatation response 6.3%±7.8% -9%–43%
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; sD, standard deviation.
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was graded mild (3%), moderate (40%), or severe (55%). 
Two patients (2%) included in the study had no signs of 
COPD in the V/P SPECT. However, we found that both of 
these patients had a PE, and in one of them we suspected a 
lung tumor. Vgrade and TPLF% agreed well with the GOLD 
stages (r=0.63 and -0.60, respectively, P,0.0001, Figure 2). 
Vgrade and TPLF% showed a weaker correlation with the 
pulmonary function tests (Figure 3). The V/P SPECT analysis 
tended to diagnose ventilation defects earlier than spiro-
metry. Vgrade 3 had significantly lower pulmonary function 
values in spirometry than Vgrade 2 (Figure 4). Emphysema 
was identified in 81 patients (86%). TPLF% varied from 
15%–80% (mean 38%).
PE was found in 30 patients (32%), and LHF was pres-
ent in 26 patients (28%). Findings suspicious for tumors 
were identified in 15 patients (16%), and pneumonia was 
reported in 4 patients (4%). Several patients had more than 
one comorbidity (Figure 5).
In the ordinary clinical examination, 23% of the patients 
were found to have emphysema, 4% PE, 6% lung cancer, 5% 
pneumonia, 1% acute bronchitis, 1% pulmonary tuberculosis 
under treatment, and 1% bronchiectasis. Their concomitant 
extrapulmonary diagnoses included hypertension (19%), 
coronary artery disease (9%), and chronic heart failure (2%). 
Other diagnoses include diabetes, rheumatoid arthritis, and 
gastrointestinal diseases (altogether 19%).
Figure 1 V/P sPeCT of a patient with a severe COPD (gOlD 3).
Notes: On the frontal slice, uneven distribution of ventilation and absent ventilation are seen, as is perfusion in the upper lobe (blue arrows indicating emphysema). hot 
spots represent changes in small airway disease (dotted blue arrow on sagittal slice).
Abbreviations: gOlD, global Initiative for Chronic Obstructive lung Disease; V/P sPeCT, ventilation/perfusion single-photon emission computed tomography.
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Figure 2 Correlation between Vgrade and TPlF% and gOlD stages.
Note: Pearson correlation coefﬁcients and linear regression lines with best-ﬁt values (continuous line) and 95% conﬁdence intervals (dotted lines) are presented.
Abbreviations: gOlD, global Initiative for Chronic Obstructive lung Disease; TPlF%, total preserved lung function; sPeCT, single-photon emission computed tomography; 
Vgrade, penetration grade of Technegas in V sPeCT.
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Figure 3 Correlation between Vgrade and TPlF% and results of the technically accepted and reproducible pulmonary lung function tests.
Note: Pearson’s correlation coefﬁcients and linear regression lines with best-ﬁt values (continuous line) and 95% conﬁdence intervals (dotted lines) are presented.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; TPlF%, total preserved lung function; sPeCT, single-photon emission computed 
tomography; Vgrade, penetration grade of Technegas in V sPeCT.
Discussion
V/P SPECT is a new tool to diagnose COPD and to grade 
its severity.27 In this study, Vgrade and TPLF% agreed well 
with GOLD stages.19,27 V/P SPECT also revealed pulmonary 
comorbidities with vascular and ventilatory defects, which 
contribute to the heterogeneity of COPD. Emphysema was 
a more frequent finding than clinically expected. All V/P 
SPECT findings were diagnostic.
The small hydrophobic aerosol property of Technegas 
enables its penetrations into the smallest conducting airways, 
and then finally by diffusion reaching the alveolar level.31 
Technegas penetration depends on the small airway func-
tion, and bronchial deposition increases in small airway 
disease allowing detection of airway obstruction earlier by 
Technegas ventilation image than by spirometry.19,32 In a 
study by Jobse et al,18 small airways disease was predicted 
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by the ventilation/perfusion pattern on V/P SPECT. The 
authors suggest that the hot spots representing exaggerated 
deposition of Technegas in the airways appear when nar-
rowing is sufficiently severe to cause airflow limitations 
(Figure 1). Our results regarding Vgrade and its relation to 
different degrees of obstructive small airways disease agree 
with earlier published data.11,19,27,32–34 In the present study, 
most of the patients had an advanced obstructive disease, 
favoring the good correlation between the V/P SPECT and 
spirometry in measuring airway obstruction.
PE was the most frequent comorbidity and was seen 
in 32% of patients. The perfusion defects were typically 
segmental or subsegmental mismatches, and some were 
probably residuals after earlier acute untreated PEs. In two 
cases, the V/P SPECT detected vascular defects (and also 
one suspicion of a lung tumor) in the absence of any signs of 
COPD on V/P SPECT. Both patients were included into the 
study on the basis of symptoms and obstructive lung func-
tion findings suggesting COPD. The vascular defect might 
explain the patients’ dyspneic symptoms in these cases. 
One patient actually received a clinical diagnosis of PE and 
lung cancer. The PE was a previously unknown finding in 
another patient. Asthma with reversible obstruction cannot 
be excluded in these cases.
An acute PE may often remain undiagnosed in COPD 
patients. Usually, PE is diagnosed at the time of COPD 
exacerbation with no clear etiology.35 In a recent systematic 
review by Aleva et al,36 the pooled prevalence of PE was 
16% (confidence interval [CI] 8.3%–25.8%) in a total of 880 
COPD patients. PE seems to increase mortality and length 
of hospital admission.36
In our study, only four patients were known to have 
had PE before V/P SPECT imaging, and three of them still 
showed perfusion defects in this study. Earlier studies show 
that even treated patients might have residual perfusion 
defects.16,37,38 It is known that the vascular response is often 
impaired in COPD patients.39
The second most important comorbidity was signs of LHF, 
present in 28% of the COPD patients. Generally, it is known 
that COPD and chronic heart failure frequently coexist.40 In 
?
?????
???
?????
???
?????
???
??
??
??
??
???
??? ????????
???
??
?
?????
???
?????
???
?????
???
??
??
??
??
???
??? ????????
???
????
??
?
?????
???
?????
???
?????
???
??
??
??
??
???
??? ??????
???
?
Figure 4 Vgrade 1, 2, and 3 in relation to the technically accepted and reproducible lung function test results (n=75).
Note: The plots of measurements with the mean and the 95% conﬁdence intervals are shown.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; sPeCT, single-photon emission computed tomography; Vgrade, penetration grade 
of Technegas in V sPeCT.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
21
4.
59
.1
63
 o
n 
11
-J
ul
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1585
COPD with V/P sPeCT
patients hospitalized with heart failure, COPD was diagnosed 
in 30%–36% of the patients.41,42 Obviously, this clinical condi-
tion is a diagnostic challenge owing to the fact that patients 
with COPD, LHF, and PE have similar and nonspecific symp-
toms in the form of dyspnea, cough, exercise intolerance, and 
fatigue. Chest X-ray, electrocardiogram, CT, and spirometry 
might be misleading diagnostic procedures for this complex 
status. LHF is known to have a prognostic impact.43,44
These results highlight the heterogeneity of COPD. 
As many as 58 (62%) subjects among the total number of 
94 studied COPD patients had 1 or more comorbidities that 
were capable of being identified with V/P SPECT. These 
findings might have an impact on treatment in this subgroup 
of COPD patients. In some patients, the reason for exacer-
bations might be an acute PE or an acute LHF. We do not 
know of any method, other than V/P SPECT, that might 
diagnose both the severity and heterogeneity of COPD with 
pulmonary comorbidities. Therefore, the study raises the 
question of how frequently the V/P SPECT procedure is 
indicated for the diagnosis and classification of COPD or 
COPD exacerbation.
The limitation of this study is the dominance of men 
among the enrolled patients and the absence of a control 
group. High-resolution CT could be of added value for 
diagnosing nodular changes and to allow better delineation 
of emphysema. Further studies are required to measure the 
degree of obstructive small airways disease by V/P SPECT, 
particularly in “healthy smokers” with a normal pulmonary 
function on spirometry.
Conclusion
V/P SPECT could diagnose and grade severity of COPD, 
and estimate preserved lung function. Even more important, 
V/P SPECT appears to be a unique physiological method to 
reveal pulmonary comorbidities with vascular and ventila-
tory defects, which contribute to the heterogeneity of COPD. 
???????????
???
?????
???
???
????
??
???
????
????
?
??????? ???????????????????
Figure 5 V/P sPeCT of a patient with a severe COPD (gOlD 3).
Note: Uneven distribution of ventilation with hot spots (indicating obstructive small airways disease), area with absent ventilation and perfusion in the upper lobe (blue 
arrows indicating emphysema), as well as area with absent perfusion and preserved ventilation (mismatch – red arrows indicating pulmonary embolism).
Abbreviations: gOlD, global Initiative for Chronic Obstructive lung Disease; V/P sPeCT, ventilation/perfusion single-photon emission computed tomography.
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The characteristics of these comorbidities suggest their impact 
on the symptoms, treatment, and prognosis of patients.
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